OncoMatch/Clinical Trials/NCT05690581
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
Is NCT05690581 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CM369 for advanced solid tumors and hematologic malignancies.
Treatment: CM369 — This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Tumor Agnostic
Biomarker criteria
Required: CCR8 positive (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with immune checkpoint inhibitors
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: allowed if >100 days prior to first investigational medications dose
Autologous hematopoietic stem cell transplantation within 100 days prior to first investigational medications dose
Cannot have received: allogeneic hematopoietic stem cell transplantation
history of allogeneic hematopoietic stem cell transplantation
Cannot have received: any anti-tumor therapy
Exception: allowed if >28 days prior to first investigational medications dose
Have had any therapy directed against the subject's underlying cancer within 28 days prior to first investigational medications dose
Cannot have received: other clinical trial drugs
Exception: allowed if >28 days prior to first investigational medications dose
Received other clinical trial drugs within 28 days prior to first investigational medications dose
Lab requirements
Blood counts
Adequate hematological function, defined as protocol.
Kidney function
Adequate renal function, defined as protocol.
Liver function
Adequate hepatic function, defined as protocol.
Cardiac function
Adequate cardiac function, defined as protocol.
Have adequate organ function as described in the protocol. Adequate hematological function, defined as protocol. Adequate hepatic, renal and cardiac functions, defined as protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify